Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability.

BACKGROUND Patients with an activated renin-angiotensin system (RAS) or genetic alterations of the RAS are at increased risk of myocardial infarction (MI). Administration of ACE inhibitors reduces the risk of MI, and acute coronary syndromes are associated with increased interleukin 6 (IL-6) serum levels. Accordingly, the present study evaluated the expression of angiotensin II (Ang II) in human coronary atherosclerotic plaques and its influence on IL-6 expression in patients with coronary artery disease. METHODS AND RESULTS Immunohistochemical colocalization of Ang II, ACE, Ang II type 1 (AT(1)) receptor, and IL-6 was examined in coronary arteries from patients with ischemic or dilated cardiomyopathy undergoing heart transplantation (n=12), in atherectomy samples from patients with unstable angina (culprit lesion; n=8), and in ruptured coronary arteries from patients who died of MI (n=13). Synthesis and release of IL-6 was investigated in smooth muscle cells and macrophages after Ang II stimulation. Colocalization of ACE, Ang II, AT(1) receptor, and IL-6 with CD68-positive macrophages was observed at the shoulder region of coronary atherosclerotic plaques and in atherectomy tissue of patients with unstable angina. Ang II was identified in close proximity to the presumed rupture site of human coronary arteries in acute MI. Ang II induced synthesis and release of IL-6 shortly after stimulation in vitro in macrophages and rat smooth muscle cells. CONCLUSIONS Ang II, AT(1) receptor, and ACE are expressed at strategic sites of human atherosclerotic coronary arteries, suggesting that Ang II is produced primarily by ACE within coronary plaques. The observation that Ang II induces IL-6 and their colocalization with the AT(1) receptor and ACE is consistent with the notion that the RAS may contribute to inflammatory processes within the vascular wall and to the development of acute coronary syndromes.

[1]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[2]  C. Sobey,et al.  Evidence that macrophages in atherosclerotic lesions contain angiotensin II. , 1998, Circulation.

[3]  A. Lazzarin,et al.  Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. , 1998, Blood.

[4]  G. Callis,et al.  Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Breslow,et al.  The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. , 1997, Biochemical and biophysical research communications.

[6]  D. Remick,et al.  Regulatory effects of interleukin-6 in immunoglobulin G immune-complex-induced lung injury. , 1997, The American journal of pathology.

[7]  F. Neumann,et al.  Induction of cytokine expression in leukocytes in acute myocardial infarction. , 1997, Journal of the American College of Cardiology.

[8]  P. Kovanen,et al.  Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. , 1997, Circulation.

[9]  J. Egido,et al.  Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. , 1997, Circulation.

[10]  A. Mantovani,et al.  The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment. , 1997, Drugs.

[11]  P. Kovanen,et al.  Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. , 1996, Circulation.

[12]  G. Berry,et al.  Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. , 1996, Circulation.

[13]  G. Ciliberto,et al.  Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.

[14]  M. Marrero,et al.  Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. , 1996, Hypertension.

[15]  T. Paavonen,et al.  Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. , 1995, Circulation.

[16]  P. Constantinides.  Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. , 1995, Circulation.

[17]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[18]  M. Aviram,et al.  Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. , 1995, Atherosclerosis.

[19]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[20]  M. Aviram.  Oxidative modification of low density lipoprotein and its relation to atherosclerosis. , 1995, Israel journal of medical sciences.

[21]  P. Kovanen,et al.  Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. , 1994, Circulation.

[22]  V. Fuster,et al.  Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.

[23]  L. Tiret,et al.  Plasma Level and Gene Polymorphism of Angiotensin‐Converting Enzyme in Relation to Myocardial Infarction , 1994, Circulation.

[24]  P. Libby,et al.  Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. , 1994, Circulation research.

[25]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[26]  U. Ikeda,et al.  Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines. , 1993, Atherosclerosis.

[27]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[28]  D. Steinberg,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.

[29]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[30]  A. Chobanian,et al.  Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1992, Hypertension.

[31]  R D Kamm,et al.  Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. , 1992, Circulation research.

[32]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[33]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[34]  Intracranial hemorrhage in blacks as compared with whites. , 1992, The New England journal of medicine.

[35]  R. Hamanaka,et al.  Induction of low density lipoprotein receptor and a transcription factor SP-1 by tumor necrosis factor in human microvascular endothelial cells. , 1992, The Journal of biological chemistry.

[36]  S. Rankin,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1992, Progress in lipid research.

[37]  J. Laragh,et al.  Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.

[38]  M. Daemen,et al.  Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. , 1991, Circulation research.

[39]  A. Gearing,et al.  Induction of in vitro human lymphocyte migration by interleukin 3, interleukin 4, and interleukin 6. , 1990, Cytokine.

[40]  G. Åberg,et al.  Effects of Captopril on Atherosclerosis in Cynomolgus Monkeys , 1990, Journal of cardiovascular pharmacology.

[41]  H. Baumgartner,et al.  Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. , 1989, Science.

[42]  B. Waeber,et al.  Angiotensin II measurement with high‐affinity monoclonal antibodies , 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[43]  J. Weinstock,et al.  Angiotensin II is chemotactic for a T-cell subset which can express migration inhibition factor activity in murine schistosomiasis mansoni. , 1987, Cellular immunology.

[44]  G. Bondjers,et al.  Regional Accumulations of T Cells, Macrophages, and Smooth Muscle Cells in the Human Atherosclerotic Plaque , 1986, Arteriosclerosis.

[45]  M J Davies,et al.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. , 1985, British heart journal.